Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face

British Journal of Dermatology

Volumn 163, Issue 1, 2010, Pages 225-227

  Rosen, A ^a   Thimon, S ^a   Ternant, D ^a   MacHet, M C ^a,b   Paintaud, G ^a,b   MacHet, L ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

angiosarcoma; bevacizumab; pharmacology; skin cancer

Indexed keywords

BEVACIZUMAB;

AGED; ANGIOSARCOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS ANGIOSARCOMA; ECCHYMOSIS; FEMALE; HUMAN; LETTER; LYMPHADENOPATHY; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FACIAL NEOPLASMS; FEMALE; HEMANGIOSARCOMA; HUMANS; TREATMENT OUTCOME;

EID: 77953965177     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09803.x     Document Type: Letter

References (5)

1. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006 28 : 1779 1802.
2. Azizi AA, Haberler C, Czech T et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 2006 7 : 521 523.
3. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005 23 : 2544 2555.
4. Lu JF, Bruno R, Eppler S et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008 62 : 779 786.
5. Koontz BF, Miles EF, Rubio MA et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008 30 : 262 266.